Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/37823
Title: Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.
Authors: Bower, Hannah
Björkholm, Magnus
Dickman, Paul W.
Höglund, Martin
Lambert, Paul C.
Andersson, Therese M.-L.
First Published: 20-Jun-2016
Publisher: American Society of Clinical Oncology
Citation: Journal of Clinical Oncology, 2016, JCO662866
Abstract: PURPOSE: A dramatic improvement in the survival of patients with chronic myeloid leukemia (CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor (TKI). We assessed how these changes affected the life expectancy of patients with CML and life-years lost as a result of CML between 1973 and 2013 in Sweden. MATERIALS AND METHODS: Patients recorded as having CML in the Swedish Cancer Registry from 1973 to 2013 were included in the study and followed until death, censorship, or end of follow-up. The life expectancy and loss in expectation of life were predicted from a flexible parametric relative survival model. RESULTS: A total of 2,662 patients with CML were diagnosed between 1973 and 2013. Vast improvements in the life expectancy of these patients were seen over the study period; larger improvements were seen in the youngest ages. The great improvements in life expectancy translated into great reductions in the loss in expectation of life. Patients of all ages diagnosed in 2013 will, on average, lose < 3 life-years as a result of CML. CONCLUSION: Imatinib mesylate and new TKIs along with allogeneic stem cell transplantation and other factors have contributed to the life expectancy in patients with CML approaching that of the general population today. This will be an important message to convey to patients to understand the impact of a CML diagnosis on their life. In addition, the increasing prevalence of patients with CML will have a great effect on future health care costs as long as continuous TKI treatment is required.
DOI Link: 10.1200/JCO.2015.66.2866
eISSN: 1527-7755
Links: http://jco.ascopubs.org/content/early/2016/06/15/JCO.2015.66.2866.full
http://hdl.handle.net/2381/37823
Embargo on file until: 20-Dec-2016
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © American Society of Clinical Oncology, 2016. This article is distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Description: Following the embargo period the file associated with this record is available with the above license.
Appears in Collections:Published Articles, Dept. of Health Sciences

Files in This Item:
File Description SizeFormat 
CML_revised_manuscript20160308.pdfPost-review (final submitted author manuscript)510.92 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.